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Anisoylated plasminogen streptokinase activator com-
plex (APSAC) was developed as a second generation
thrombolytic agent in an attempt to overcome some of
the limitations to the intravenous application of strep-
tokinase for coronary artery thrombolysis. Temporary
protection of the active site on the plasminogen molecule
by acylation allows APSAC to be given by rapid injec-
tion, confers semiselectivity for clot (at lower doses) and
prolonged fibrinolytic action. These properties may sim-
plify intravenous administration, improve coronary re-
perfusion response and reduce reocclusion potential.
Clinical trials with APSAC, still ongoing, allow the fol-
lowing tentative conclusions: the efficacy of intravenous
APSAC appears to be equivalent to that of intracoronary
streptokinase, when given within 4 hours of the onset of
Rationale for APSAC and
Biochemical Properties
Streptokinase has certain disadvantages as a thrombolytic
agent for intravenous application. On injection, streptoki-
nase forms a complex with plasminogen and is then subject
to rapid degradation by plasma anti activators; it also causes
nonspecific fibrinogenolysis and plasminemia leading to a
systemic lytic state. Bleeding risk increases and activity that
might otherwise be directed toward pathologic clot is wasted,
To improve the kinetic properties of the streptokinase-plas-
minogen complex, chemical "protection" of the active site
un the plasminogen molecule has been undertaken with var-
ious acyl groups, Among these acyl streptokinase-plasmin-
ogen compounds, the anisoylated plasminogen-streptoki-
nase activator complex (APSAC) (BRL 26921) has been
selected for clinical testing (Fig. I) (I),
Kinetics. APSAC is inactive on injection, but activation
by hydrolysis begins immediately and in a controlled fashion
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symptoms of myocardial infarction, and superior to that
of intravenous streptokinase, but it is easier to admin-
ister. Early APSAC therapy leads to reperfusion rates
of 60 to 65% and patency rates of 70 to 80%. Early
reocclusion rates (within 24 hours) appear to be as low
as or lower than those obtained with other agents. Bleed-
ing complications and allergic manifestations after
APSAC are acceptably low and comparable with those
of equivalent doses of streptokinase. The potential for
mortality benefit after APSAC appears to be high and
is undergoing additional study. Thus, APSAC therapy,
which can be ~iven by simple injection over 2 to 5 min-
utes, appears promising as a future first line approach
to reperfusion therapy in acute myocardial infarction.
(J Am CoIl CardioI1987;lO:22B-7B)
(2-4), The deacylation (activation) half-life in plasma is
approximately 90 to 105 minutes (4). Deacylation appears
to be the limiting factor in clearance of fibrinolytic activity,
which has a similar half-life. These kinetic properties result
in controlled activation of fibrinolytic activity and more
gradual clearance of activity (clearance half-life 90 to 105
minutes). Thus, fibrinolytic activity is present for 4 to 6
hours after administration of APSAC, versus < I hour after
administration of streptokinase, which has a clearance half-
life of about 10 to 18 minutes. In addition, the acyl form
protects the activator complex from nonspecific neutraliza-
tion by plasma inhibitors and autodigestion is attenuated,
but fibrin-binding sites are not affected. Thus, on injection,
nonspecific tlbrinogenolysis and inactivation are reduced,
but effective, rapid binding of circulating complex to fibrin
clots occurs. Deacylation then leads to controlled and sus-
tained fibrinolytic activity that appears in a semiselective
fashion at the site of clot, providing efficient thrombolysis,
Experience With APSAC in
Preclinical Studies
Preclinical studies suggest the following advantages for
acylation of the plasminogen streptokinase activator com-
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Figure I. Structure of anisoylated plasminogen streptokinase ac-
tivator complex (APSAC). PLG = plasminogen; SK = strepto-
kinase.
plex: I) administration by simple rapid injection without
adverse effects, 2) improved lytic potency and semiselec-
tivity for clot, 3) controlled plasma clearance with sustained
activity, and 4) superior clot retention (3).
Rapid intravenous injection of streptokinase hut not
APSAC leads to unacceptable hypotension. In a canine study,
equivalent bolus injections of streptokinase-plasmin (equiv-
alent to 2 million units of streptokinase in humans) and
APSAC (50 mg = 50 units) were compared (5). Strepto-
kinase injections led to profound hypotension within 3 min-
utes (50% reduction in mean blood pressure), whereas
APSAC injections did not affect blood pressure. In these
studies. streptokinase injections were associated with abrupt
generation of large quantities of plasmin. whereas APSAC
caused gradual and controlled plasmin generation. (Plasmin
generation causes activation of the kininogen system with
production of bradykinin, a potent vasodilator that may be
responsible for the hypotension observed with strepto-
kinase.)
Experimentally. APSAC has shown greater lytic potency
than have equivalent doses of streptokinase in various
thrombosis models (6). In a guinea pig in vivo pulmonary
embolism model, for example. the dose-response curve for
APSAC was shifted substantially to the left of that for strep-
tokinase-plasmin (3).
ln other studies, clot binding and penetration in vivo
l1'ere shown to he greater for APSAC thanfor streptokinase
or urokinase (3,7). After immersion of thrombi for I minute
in plasma containing equivalent concentrations of these three
agents, thrombolysis over a subsequent period of 5 hours
was 60% for APSAC but < 10% of the clot mass for uro-
kinase or streptokinase.
Clinical Experience With APSAC for Acute
Myocardial Infarction
A number of initial observations in small controlled stud-
ies have suggested that APSAC is a promising fibrinolytic
agent for acute myocardial infarction (8-11). APSAC may
be administered by the intracoronary route with results sim-
ilar to those expected for intracoronary streptokinase. In a
German study (10). intracoronary APSAC caused reperfu-
sion in 15 (68%) of 22 patients at a mean of 42 :!:: 37
minutes. However, the unique features of APSAC favor its
application for intravenous use.
Several earlv feasibility studies (8-16), performed pri-
marilv in Europe, indicated substantial potential for the
application of APSAC in acute myocardial infarction. In
European dose comparison studies (16), coronary patency
rates of about 30 to 40% were observed for 5 units, 40 to
5Wk for 15 units, 60% for 20 to 25 units and up to 80%
for 30 units. Doses of 2'"10 units were, however, also as-
sociated with significant systemic fibrinogenolysis.
In a United States study, Marder et al. (15) administered
doses totaling 5. 15 and 30 units of APSAC to 29 patients
with acute myocardial infarction and angiographically doc-
umented coronary occlusion. Reperfusion occurred in 3 (21 %)
of 14 patients given 5 units, 3 (43%) of 7 given 15 units
and 9 (60%) of 15 given 30 units. "Salvage" therapy with
intracoronary streptokinase was subsequently given to pa-
tients in whom APSAC therapy had failed, to optimize
thrombolytic reperfusion. In comparison with the total num-
ber of patients with acute infarction eventually achieving
reperfusion, APSAC was found to be effective in 25% given
5 units. 50% given [5 units and 83% of thrombolysis-
susceptible patients given 30 units.
As oithe end (i 1986. APSAC had been administered to
almost 1,500 patients participating in a variety (~r studies
worldwide (16). In patients undergoing angiography, av-
erage patency (or reperfusion) rates of 67% have been ob-
served. A similar success rate has also been suggested by
other studies using noninvasive indexes of reperfusion. Im-
portant controlled comparisons from larger, selected studies
are more enlightening, as summarized later.
Comparisons of Intravenous APSAC With
Intracoronary Streptokinase
lntracoronary streptokinase represents the Food and Drug
Administration-approved reference standard for thrombo-
lytic therapy in the United States. Initial evaluation of new
thrombolytic agents requires their comparison to accepted
standards.
United States Randomized Trial
In the United States. a randomized multicenter trial (17)
is nearing completion comparing the rcpcrfusion potential
of intravenous APSAC and intracoronary streptokinase ad-
ministered according to the FDA-approved dosing regimen.
Patients with clinical and electrocardiographic criteria for
acute transmural myocardial infarction who could be studied
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angiographically within 6 hours of symptom onset were
candidates for study entry. After giving informed consent.
patients were studied angiographically, and those with coro-
nary occlusion of the infarct-related artery (flow grade 0 or
I, Thrombolysis in Myocardial Infarction [TIMI] criteria)
(18) were randomized to therapy. (Flow grades 0 and 1 =
no or minimal flow; grades 2 and 3 = complete and delayed
or normal flow.) After confirmation of coronary occlusion,
patients were randomized to receive either APSAC, 30 units
by intravenous injection over 2 to 4 minutes, or streptoki-
nase, 20,000 unit bolus injection followed by intracoronary
administrationof 2,000 units/minfor 60 minutes. Successful
reperfusion was defined as grade 2 or 3 flow at 90 minutes
as assessed by a reader unaware of treatment received.
An interim analysis of the first 93 entered patients has
recently been reported (17). Treatment was accomplished
at a mean of 3.4 hours after symptom onset. The angio-
graphic success rate was similar for intravenous APSAC
and for intracoronary streptokinase therapy, particularly in
subgroups of patients treated within 4 hours of symptom
onset. For patients treated within 4 hours, reperfusion after
APSAC averaged 56% (15 of 27 patients). compared with
25% (4 of 16 patients) treated after 4 hours. A similar time
dependence has been observed for intravenousstreptokinase
in the TIMI study (18), in which a 44% reperfusion rate
was achieved for treatment within 4 hours as compared with
a 24% success rate thereafter (A. Ross, personal commu-
nication) (Fig. 2). Intracoronary streptokinase, in contrast,
did not show significant time dependence. Clinical roper-
fusion overall averaged 49% (19 of 39 patients). However,
grade 2 or 3 reperfusion occurred at some time during cath-
eterization in 67% of streptokinase-treated patients, a figure
similar to that for streptokinase in other reported studies
(19-21 ).
The time to initial reperfusion after initiation of intra-
venous therapy was slightly longer (mean 42 minutes) than
that for intracoronary therapy (mean 30 minutes), as has
Figure 2. Comparison of reperfusion potential of intravenous an-
isoylated plasminogen streptokinase activator complex (APSAC)
(United States multicenter trial: interim results) (17) and intrave-
nous streptokinase (5K) (TIMI-I trial) (18) as a function of treat-
ment time from onset of symptoms. *p < 0.05 versus 4 hours.
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been observed for these differing routes of administration
with streptokinase (19-21). In addition to showing time
dependence, treatment success showed dependence on oc-
clusion grade. Both streptokinase and APSAC were more
successful for patients with initial grade I flow (71 % suc-
cess) than in those with grade 0 flow (38% success) (p <
0.02). Grade I flow tended to be somewhat more frequent
in patients studied earlier «4 hours) after symptom onset.
The hemodynamic tolerance to rapid injections ofAPSAC
was good. The change in mean blood pressure was ac-
ceptably small ( - 6 mm Hg) and comparable with or only
slightly greater than that of low dose, slowly administered
intracoronary streptokinase. Electrocardiographic and en-
zymatic indicatorsof infarction were generally similar (22).
Fibrinogen levels declined to a greater extent after the
larger relative doses of APSAC (30 units APSAC = 1.1
million units streptokinase) than after low dose intracoro-
nary streptokinase (total 150,000 units). Fibrinogen levels
declined to 39% of control 90 minutes after APSAC, com-
pared with 64% of control after streptokinase (23). In par-
allel with these changes, bleeding was noted in 12 patients
after APSAC and in 5 after low dose streptokinase. How-
ever, 10 of the 12 bleeding events with APSAC occurred
at the arterial site of catheter entry, and only 1 required
transfusion. There was one instance each of hemoptysis,
hernaternesis and hematuria after APSAC, but no intra-
cranial hemorrhage or mortality due to bleeding. Other re-
actions for streptokinase or APSAC were minor and related
to the infarct itself or to minor allergic phenomena. The
incidence of occlusion within 24 hours after APSAC or
streptokinase plus heparin was very low. Thus, APSAC is
approximately comparable with intracoronary streptokinase
in effectiveness, particularly when given within 4 hours,
but is easier to administer yet well tolerated.
Dutch Randomized Trial of Intravenous APSAC and
Intracoronary Streptokinase
A Dutch study (24) of similar design comparing APSAC
with intracoronary streptokinasewas recently performed. In
that study, a higher infusion rate of intracoronary strepto-
kinase was used (250,000 units over I hour), and an even
shorter mean time to initial treatment was achieved (2.4
hours), than in the United States study. Eighty-five patients
with acute myocardial infarction were randomized to intra-
venous APSAC (n = 42) or intracoronary streptokinase
(n = 43) after angiographic documentation of coronary
occlusion (grade 0 or I flow), In patients who could be
evaluated, reperfusion success (angiographic grade 2 or 3
flow at 90 minutes) was achieved in 64% of APSAC-treated
patients and 68% of streptokinase-treated patients (p = NS)
(Fig. 3). Both groups subsequently received heparin. Among
patients not receiving early mechanical intervention, reoc-
elusion at 24 hours was observed in only one APSAC-treated
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it appears reasonable to conclude on the basis of current
information that APSAC is substantially easier to administer
than is intravenous streptokinase and provides at least equiv-
alent and probably superior effi cacy and comparable safety.
These tentative conclusions suggest that APSAC may be a
preferable agent to intravenous or intracoronary streptoki-
nase for early therapy of acute myocardial infarction.
Adverse Potential of APSAC
Drug
Figure 3. Co mparison of reperfusion potential of intracoronary
streptokinase (lC SK ) and intravenous (IV) anisoylated plasmi n-
ogen streptokinase activator complex (APSAC) observed in a Dutch
randomized trial (24).
and three streptokinase-treated patients. Bleeding and other
adverse events occurred in a low and comparable number
of patients in both groups.
The results of the Dutch study underscore those (!{ the
United States multicenter study . They suggest a reperfusion
potential of 60 ± 5% for intravenous APSAC given within
4 hours to patients with total coronary occlusion. They also
document that intravenous APSAC has approximately com-
parable efficacy when compared with intracoronary strep-
tokinase and good to excellent tolerance. A low reocclusion
rate is observed for both regimens. but APSAC is easier to
administer.
Comparison of Intravenous APSAC and
Intravenous Streptokinase
In a French coronary patency study (25). 86 patients with
acute myocardial infarction were randomized within 6 hours
of the onset of symptoms to either APSAC. 30 units given
over 5 minutes. or to streptokinase, 1.5 million units infused
over I hour. Patency was defined as coronary now grade 2
or 3 at the time of angiography. performed at an average
of 90 minutes after therapy. APSAC achieved a patency
rate of 72% (28 of 39 patients) and streptokinase, 56% (24
of 43 patients) (p = 0.15) (Fig. 4). Both agents caused
comparable falls in circulating fibrinogen levels. There were
two deaths in each group (4% mortality rate). Long-term
patency after APSAC was excellent: 93% patency was oh-
served in successfully treated patients reevaluated at I to 2
weeks. These results are similar to those obtained in an
earlier European patency trial (26) of intravenous tissue
plasminogen activator compared with intravenous strepto-
kinase; patency rates of 70 and 55%. respectively. were
observed.
Further comparisons of APSAC and intravenous strep-
tokinase are being conducted in a large multicent er United
States trial that began in thefi rst quarter of /987. However.
The antigenic and hemorrhagic effects of APSAC
appear to compare with those of equivalent doses of
intravenous streptokinase.
Bleeding. Hemorrhagic events have been reported in 53
(8. 9(X) of 593 patients treated with APSACevaluated world-
wide (16). In comparison groups in these studies. bleeding
was observed in 6.3% of heparin-treated patients, 10.9C/c .
of streptokjnase-treated paticnts and 2.8% of placebo-treated
patients. The majority of significant bleeding episodes oc-
curred at the site of arterial puncture (5.4% of patients).
Gastrointestinal bleeding, hemoptysis and hernatemesis were
each reported in approximately 0.5% of patients. Hemor-
rhag ic cerebrovascular accidents occurred infrequently within
2 days of APSAC administration: Three of the six strokes
in 993 patients treated with APSAC were hemorrhagic (0.3%
incidence rate). Each of these occurred in a patient with
predisposing conditions. (Stroke was also reported in 2 of
SO patients among placebo control groups in these trialx.)
This low incidence of cerebrovascular accidents related to
APSAC is comparable with the row rate observed in intra-
venous streptokinase trials (27 .28).
Allergy. APSAC is potentially allergenic. but the inci-
dence of allergic-related events has been low and rarely
problematic. Reactions potentially allergic in nature have
been reported in 1.9% of patients receiving APSAC and
have included rash ((l.8o/d, erythema or other allergy (0.2%
each), bronc hocons tric tion (0 .5 %) and o ne instance each of
Figure 4 . Co mparison of reperfusio n potentia l of intravenous (1V)
unisoylatcd plas minogen streptok inase activator complex (APSAC)
(30 units ) and intravenous streptokinase (SK) ( 1.5 million units )
in a French randomized patency trial (25) .
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probable anaphylaxis and angioedema (0.2%) (16). In each
case, resolution has occurred with observation or standard
medical therapy, and no mortality has resulted.
Reocclusion. The fibrinolytic activity of APSAC ap-
pears to confer a low reocclusion potential. Among suc-
cessfully treated patients not undergoing mechanical inter-
vention and restudied at least 24 hours after administration
of 30 units of APSAC, reocclusion was reported in only 2
(3.4%) of 58 patients, compared with 5 (7.6%) of 66 com-
parative patients treated with streptokinase (16,24).
APSAC Therapy and Early Mortality in
Acute Myocardial Infarction
Large randomized mortalitystudies, comparablewith the
Italian Group for the Study of Streptokinase in Myocardial
Infarction [GISSIj study (28) with intravenous streptoki-
nase, have not yet been performed with APSAC. However,
available evidence suggests the potential for mortality re-
duction with APSAC therapy. Combiningthe availableclin-
ical data base (16), an early mortality rate of6.I% has been
observed after APSAC(85 of I ,386 patients)compared with
an early mortality rate of 9.5% in control patients receiving
either placebo or standard therapy (55 of 576 patients). In
the United Kingdom, a major study (29) among several
thousand patients with acute myocardial infarction treated
with APSAC or placebo has been initiated. This study has
been designated AIMS (APSAC in a myocardial infarction
study). Previously, a feasibility study (30) has been re-
ported: mortality occurred in I of 43 patients receiving
APSAC compared with 7 of 42 receiving placebo. In a
controlled community hospital study (31), mortality within
9 months of acute myocardial infarction occurred in 7 of
74 patients treated with APSAC compared with 13 of 73
untreated control patients (p < 0.01).
Summary
Based on current evidence, intravenous APSAC appears
to be equivalent to intracoronary streptokinase and superior
to intravenous streptokinase in efficacy, but it is easier
to administer and has a low reocclusion rate. Like strep-
tokinase, reperfusion success with APSAC is time depen-
dent; reperfusion potential is 60 to 65°4:1 when APSAC is
administeredwithin 3 to 4 hours of total coronaryocclusion.
Given the 10 to 20% rate of subtotal occlusion in acute
myocardial infarction, early administration of APSAC «2
to 4 hours) may be expected to lead to an early patency rate
of 65 to 70%. Bleeding complications and allergic mani-
festations after APSAC arc acceptable and comparable with
those in patients receivingsimilardoses of intravenous strep-
tokinase. The potential for a mortality benefit with intra-
venous APSAC appears to be high and is undergoing ad-
ditional study. Hemodynamic tolerance to rapid injections
of APSAC (over 2 to 5 minutes) has been excellent and
appears superior to that of longer infusions (30 to 60 min-
utes) of high dose streptokinase. APSAC thus appears to be
a very promising thrombolytic agent for use in a number of
clinical therapeutic settings for acute myocardial infarction,
including initial therapy in community and referral hospi-
tals, emergency rooms and, potentially, mobile coronary
care units. In these settings, APSAC should compete ef-
fectively with streptokinaseand urokinase. Because APSAC
is easier to administer and may have a lower reocclusion
potential than that of tissue plasminogen activator, direct
comparisons between these new agents in the future will be
of interest. It is anticipated that APSAC may be available
for clinical use in the United States as early as 1988.
(APSAChas recently beenapprovedfor use in both Belgium
and Germany and is due for early release in several other
European countries.)
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